Weiss Ratings Reaffirms "Sell (D-)" Rating for Insmed (NASDAQ:INSM)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for Insmed (NASDAQ:INSM), indicating ongoing concerns about the company's stock performance.
• A majority of analysts have a more positive view, with 19 equity analysts rating Insmed as a "Buy," predicting a consensus target price of $149.06.
• Insmed reported a quarterly loss of ($1.70) earnings per share, missing analysts' estimates but showing an 18.9% year-over-year revenue increase.

Insmed (NASDAQ:INSM - Get Free Report)'s stock had its "sell (d-)" rating reissued by Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Other equities analysts have also recently issued research reports about the company. Truist Financial boosted their price target on Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Jefferies Financial Group lifted their target price on Insmed from $129.00 to $148.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. UBS Group lifted their target price on Insmed from $124.00 to $133.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Citigroup raised Insmed to a "buy" rating in a report on Tuesday, June 10th. Finally, HC Wainwright upped their price objective on shares of Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $149.06.

Insmed Stock Performance

Shares of INSM opened at $161.81 on Wednesday. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. The firm has a market cap of $34.20 billion, a PE ratio of -28.34 and a beta of 1.03. The company's 50 day simple moving average is $135.87 and its 200-day simple moving average is $100.65. Insmed has a 12-month low of $60.40 and a 12-month high of $163.22.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm's revenue for the quarter was up 18.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Insmed will post -4.56 EPS for the current year.

Insider Activity at Insmed

In other news, CEO William Lewis sold 6,865 shares of Insmed stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $128.40, for a total transaction of $881,466.00. Following the completion of the sale, the chief executive officer directly owned 233,924 shares in the company, valued at approximately $30,035,841.60. This trade represents a 2.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Roger Adsett sold 25,000 shares of Insmed stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the sale, the chief operating officer owned 105,637 shares of the company's stock, valued at approximately $13,477,168.46. The trade was a 19.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 219,568 shares of company stock worth $28,305,070. 3.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Insmed

Institutional investors and hedge funds have recently made changes to their positions in the business. Hilltop National Bank purchased a new stake in shares of Insmed in the 2nd quarter worth about $28,000. ORG Partners LLC raised its position in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 196 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Insmed during the 2nd quarter worth approximately $33,000. Cullen Frost Bankers Inc. increased its stake in shares of Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 221 shares in the last quarter. Finally, LRI Investments LLC purchased a new position in shares of Insmed during the 2nd quarter worth approximately $59,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.